Pennington, Luke F. http://orcid.org/0000-0002-7947-8714
Gasser, Pascal http://orcid.org/0000-0003-3708-1660
Kleinboelting, Silke
Zhang, Chensong
Skiniotis, Georgios http://orcid.org/0000-0003-0238-7846
Eggel, Alexander http://orcid.org/0000-0001-8746-3339
Jardetzky, Theodore S. http://orcid.org/0000-0002-3664-0072
Funding for this research was provided by:
Fondation Acteria
Uniscientia Stiftung
Research Fund of the Swiss Lung Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI120510, AI115469)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL141493)
Article History
Received: 19 March 2021
Accepted: 11 November 2021
First Online: 3 December 2021
Competing interests
: L.F., A.E. and T.S.J. are shareholders and co-founders of Excellergy, a company developing new therapeutic molecules for multiple diseases. All other authors declare no competing interests.